Dacomitinib recommended as first-line treatment for NSCLC

Research has shown that dacomitinib significantly improves progression-free survival over gefitinib in EGFR-mutation-positive NSCLC.
Research has shown that dacomitinib significantly improves progression-free survival over gefitinib in EGFR-mutation-positive NSCLC.
De bron die u probeert te openen is alleen beschikbaar voor geregistreerde gebruikers. Om verder te gaan kunt u inloggen of een GRATIS univadis ® account aanmaken.